Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of Food Intake on Pharmacokinetics of Oral Almonertinib: A Randomized Crossover Trial in Healthy Chinese Participants.

Clinical pharmacology in drug development - 1 Sept 2022

Ji Wei, Jiang Yu, Wei Yilin, He Kun, Mu Hongli, Wen Qing, Zhang Xiaoran

Abstract excerpt

The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) almonertinib (HS-10296) targets both EGFR-sensitizing and T790M resistance mutations. This randomized, open-label, two-period crossover trial investigated the effect of food intake on the single-dose pharmacokinetic properties of almonertinib and its metabolite HAS-719. Twenty healthy adults received a single dose of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Administration, Oral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Over Studies

Share to Eating

Share to Healthy Volunteers

Share to Indoles

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Source

Identifiers

PMID: 35437951
DOI: 10.1002/cpdd.1095

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of Food Intake on Pharmacokinetics of Oral Almonertinib: A Randomized Crossover Trial in Healthy Chinese Participants.PMID 35437951Read ↗

Effects of food and race on the pharmacokinetics of lazertinib in healthy subjects and patients with EGFR mutation-positive advanced non-small cell lung cancer.Semantic proximity Read ↗

Effect of autoinduction and food on the pharmacokinetics of furmonertinib and its active metabolite characterized by a population pharmacokinetic model.Semantic proximity Read ↗

Nutritional status and drug resistance in EGFR-mutant NSCLC: a retrospective cohort study on almonertinib efficacy.Semantic proximity Read ↗

The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics.Semantic proximity Read ↗

Optimization of a sensitive and reliable UPLC-MS/MS method to simultaneously quantify almonertinib and HAS-719 and its application to study the interaction with nicardipineSemantic proximity Read ↗

Effect of food and polymorphisms in SLCO2B1, CYP3A4 and UGT1A4 on pharmacokinetics of abiraterone and its metabolites in Chinese volunteers.Semantic proximity Read ↗

Safety and pharmacokinetic profile of pretomanid (PA-824) in healthy Chinese participants: Results of a phase I single dose escalation studySemantic proximity Read ↗

Effects of voriconazole and fluconazole on the pharmacokinetics of almonertinib in rats by UPLC-MS/MS.Semantic proximity Read ↗

The inhibitory effect of isavuconazole on almonertinib metabolism and its underlying mechanismSemantic proximity Read ↗

Evaluation of the Effect of Ritlecitinib on the Pharmacokinetics of Caffeine in Healthy ParticipantsSemantic proximity Read ↗

Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patientsSemantic proximity Read ↗

Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.